Metraipolis › archive › dc_fd4ad120e1cd

Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients — Europe PMC PMID:42260239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42260239
DOI
10.1007/s00415-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-10-31T16:52:32.511Z
SHA-256 of the archived text
3c541cdeadb1e68a604b9c417a92215c8170cfe25d08c7d1593ef42de225048e
Stable URL of this page
https://metraipolis.com/documento/dc_fd4ad120e1cd

How to cite

Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients — Europe PMC PMID:42260239 — Europe PMC (en), https://europepmc.org/article/MED/42260239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fd4ad120e1cd (Metraipolis archive dc_fd4ad120e1cd, sha256 3c541cdeadb1e68a604b9c417a92215c8170cfe25d08c7d1593ef42de225048e)
BibTeX
@misc{dcfd4ad120e1cd,
  title = {Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients — Europe PMC PMID:42260239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42260239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fd4ad120e1cd; sha256 3c541cdeadb1e68a604b9c417a92215c8170cfe25d08c7d1593ef42de225048e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42260239. Agents can read the archived copy with the MCP tool read_document.